Ceva Animal Health Expands Investment to Advance Innovation in Vaccines, Gene Therapy

Ceva Animal Health Expands Investment to Advance Innovation in Vaccines, Gene Therapy

Ceva Animal Health, the world’s fifth-largest animal health company, has announced the restructuring of its capital. All investors, whether “Friends of Ceva” or pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company’s ability to continue its sustained growth. Ceva’s management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirm…

Hemophilia B gene therapy Hemgenix now reimbursed in Germany

The cost of the one-time hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) will now be covered for eligible patients in Germany through the country’s public healthcare system. This comes through a reimbursement price agreement between developer CSL Behring and GKV-Spitzenverband, the German National Association of Statutory Health Insurance Funds. “The agreement on the reimbursement price of Hemgenix is a decisive step for the care …